CPT code 0082U identifies a Proprietary Laboratory Analyses (PLA) test — NextGen Precision™ from Precision Diagnostics — a presumptive urine drug test that screens instrumentally for the severity of possible interactions among 90+ drugs, metabolites, and other substances. As a PLA code, 0082U maps to a single manufacturer-specific test and is used when reporting that specific assay.

This code matters nationally as PLA-designated tests are increasingly used in precision toxicology and medication management, creating distinct billing flows and coverage considerations compared with non-proprietary laboratory assays. Key payers discussed in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Payer coverage policies and reimbursement practices for PLA tests vary by plan and often hinge on medical necessity criteria and documentation of clinical utility.

Readers will find a concise overview of clinical context (presumptive urine drug interaction screening), typical service and site of service, and the payers addressed. The report summarizes benchmarks where available, notes policy and coding considerations relevant to PLA tests, and provides context for coding and claims submission. Data not available in the input will be noted as such in relevant sections.